Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6

Denise A. Yardley; Adam Brufsky; Robert E. Coleman; Pierfranco F. Conte; Javier Cortes; Stefan Glück; Jean Mark A Nabholtz; Joyce O'Shaughnessy; Robert M. Beck; Amy Ko; Markus F. Renschler; Debora Barton; Nadia Harbeck

doi:10.1186/s13063-016-1195-6

Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6

Denise A. Yardley, Adam Brufsky, Robert E. Coleman, Pierfranco F. Conte, Javier Cortes, Stefan Glück, Jean Mark A Nabholtz, Joyce O'Shaughnessy, Robert M. Beck, Amy Ko, Markus F. Renschler, Debora Barton, Nadia Harbeck

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	63
Journal	Trials
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s13063-016-1195-6
Publication status	Published - Feb 3 2016

ASJC Scopus subject areas

Medicine (miscellaneous)
Pharmacology (medical)

Access to Document

10.1186/s13063-016-1195-6

Cite this

Yardley, D. A., Brufsky, A., Coleman, R. E., Conte, P. F., Cortes, J., Glück, S., Nabholtz, J. M. A., O'Shaughnessy, J., Beck, R. M., Ko, A., Renschler, M. F., Barton, D., & Harbeck, N. (2016). Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6. Trials, 17(1), [63]. https://doi.org/10.1186/s13063-016-1195-6

Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study) : Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6. / Yardley, Denise A.; Brufsky, Adam; Coleman, Robert E. et al.

In: Trials, Vol. 17, No. 1, 63, 03.02.2016.

Research output: Contribution to journal › Article › peer-review

Yardley, DA, Brufsky, A, Coleman, RE, Conte, PF, Cortes, J, Glück, S, Nabholtz, JMA, O'Shaughnessy, J, Beck, RM, Ko, A, Renschler, MF, Barton, D & Harbeck, N 2016, 'Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6', Trials, vol. 17, no. 1, 63. https://doi.org/10.1186/s13063-016-1195-6

Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S et al. Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6. Trials. 2016 Feb 3;17(1):63. doi: 10.1186/s13063-016-1195-6

Yardley, Denise A. ; Brufsky, Adam ; Coleman, Robert E. et al. / Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study) : Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6. In: Trials. 2016 ; Vol. 17, No. 1.

@article{dff219b61e7a4f01b54020f390bc8ca0,

title = "Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6",

author = "Yardley, {Denise A.} and Adam Brufsky and Coleman, {Robert E.} and Conte, {Pierfranco F.} and Javier Cortes and Stefan Gl{\"u}ck and Nabholtz, {Jean Mark A} and Joyce O'Shaughnessy and Beck, {Robert M.} and Amy Ko and Renschler, {Markus F.} and Debora Barton and Nadia Harbeck",

note = "Erratum, non valutabile per RC, non caricato in SIPS",

year = "2016",

month = feb,

day = "3",

doi = "10.1186/s13063-016-1195-6",

language = "English",

volume = "17",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study)

T2 - Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6

AU - Yardley, Denise A.

AU - Brufsky, Adam

AU - Coleman, Robert E.

AU - Conte, Pierfranco F.

AU - Cortes, Javier

AU - Glück, Stefan

AU - Nabholtz, Jean Mark A

AU - O'Shaughnessy, Joyce

AU - Beck, Robert M.

AU - Ko, Amy

AU - Renschler, Markus F.

AU - Barton, Debora

AU - Harbeck, Nadia

N1 - Erratum, non valutabile per RC, non caricato in SIPS

PY - 2016/2/3

Y1 - 2016/2/3

UR - http://www.scopus.com/inward/record.url?scp=84956880418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956880418&partnerID=8YFLogxK

U2 - 10.1186/s13063-016-1195-6

DO - 10.1186/s13063-016-1195-6

M3 - Article

AN - SCOPUS:84956880418

VL - 17

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 63

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this